Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
| Autor: | Victor S C, Fung, Lilie, Herawati, Ying, Wan, K, Kulkantrakorn |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Dyskinesia Drug-Induced Gastrointestinal Diseases Catechols Carbidopa Catechol O-Methyltransferase Inhibitors Parkinson Disease Middle Aged Severity of Illness Index Antiparkinson Agents Levodopa Benserazide Treatment Outcome Double-Blind Method Nitriles Quality of Life Humans Drug Therapy Combination Female Enzyme Inhibitors Aged |
| Zdroj: | Movement disorders : official journal of the Movement Disorder Society. 24(1) |
| ISSN: | 1531-8257 |
| Popis: | We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double-blind study. One hundred eighty-four patients on 3 to 4 equal doses of 100/25 to 200/50 mg levodopa/carbidopa or levodopa/benserazide, 0 to 3 hours of nondisabling OFF time over a 48 hour period and no dyskinesia were randomized to levodopa/carbidopa/entacapone or levodopa/carbidopa treatment for 12 weeks. The primary outcome measure was quality of life as assessed by the PDQ-8. Secondary outcome measures were the UPDRS parts I-IV, and the Wearing Off Card. Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ-8 scores compared to treatment with levodopa/carbidopa (mean difference 1.4 points, P = 0.021). Statistically significant improvements were seen predominantly in nonmotor domains (depression, personal relationships, communication, stigma, all P0.05; dressing P = 0.056). Patients who were randomly assigned to levodopa/carbidopa/entacapone also showed significantly greater improvement in UPDRS part II scores (P = 0.032) with UPDRS part III scores showing borderline significance. Differences in UPDRS parts I and IV and Wearing Off Card scores were not significant. Treatment with levodopa/carbidopa/entacapone results in improved quality of life compared with levodopa/carbidopa in PD patients with mild or minimal, nondisabling motor fluctuations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text